Dyne Therapeutics, Inc. (DYN) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript

Dyne Therapeutics CFO Erick Lucera presented at the TD Cowen conference (Mar 4, 2026), emphasizing preparation for an upcoming commercial launch and the company's proprietary FORCE platform; no clinical data, financial metrics, or formal guidance were provided. Lucera, at Dyne about one year and a long-time industry investor, characterized the opportunity as highly compelling, signaling management confidence but offering limited actionable new information for investors.

Analysis

Dyne sits at an inflection where execution risk (commercial adoption, payer contracts, manufacturing scale) will drive valuation much more than incremental clinical data. The practical bottleneck to realizing a multi-year revenue ramp is not efficacy per se but unit-cost curve and payer pathway during the first 6–18 months of launch; faster ramp scenarios require demonstrable cost per treated patient falling toward specialty-therapy norms within the first two quarters of sales.

Competitive dynamics favor whoever secures durable formulary placement and preferred-site-of-care coding; that creates a durable moat because muscular-targeted oligonucleotide therapeutics are logistically sticky (specialty pharmacy pathways, high-touch nursing, cold chain). This will push demand upstream to oligonucleotide CDMOs and infusion/administration infrastructure — expect margin pressure or capacity premiums for suppliers over the next 12–24 months, and potential negotiating leverage for larger incumbents who can guarantee supply.

Key tail risks are reimbursement denial or narrow coverage that forces patient-by-patient appeals (6–12 month drag), and any manufacturing quality event that delays shipments (days-weeks but revenue-wise months). Conversely, early broad payer wins or a branded-code assignment could re-rate shares quickly; watch the timing and content of the first payer contracts and initial real-world adherence metrics as the immediate catalysts that will validate commercial durability.

Key Decisions for Investors

• Long DYN equity (size 2–4% portfolio) on a two-stage horizon: accumulate into weakness over the next 3–9 months while monitoring first payer announcements. Risk/reward: binary near-term downside if coverage misses, but 1.5–3x upside over 12–24 months if uptake tracks specialty norms.
• Buy DYN 9–12 month call spread (buy near-the-money, sell 20–30% OTM) to cap premium outlay while keeping asymmetric upside; limit position size to 1% portfolio. Outcome profile: limited loss = premium paid; potential 2–4x return if launch and payer cadence are positive.
• Pair trade: long DYN / short SRPT (or closest muscular dystrophy gene-therapy incumbent) — equal notional sizes to express view that differentiated delivery/administration economics could win share over single-administration gene therapies in the medium term. Timeframe 12–24 months; watch reimbursement signals as trigger to rebalance.
• Set tactical hedges: if holding material DYN exposure into initial commercial quarters, buy 6–9 month puts at strike ~15–20% below entry as protection against manufacturing or coverage shocks. Cost of hedge should be weighed against position size and liquidity; remove hedge after two consecutive quarters of positive coverage/revenue prints.